Abstract
AbstractWhile various engineering disciplines spent years on developing methods and workflows to increase their R&D efficiency, the field of cell biology has seen limited evolution in the fundamental approaches to interact with living cells. Perturbations are mostly of chemical nature, and physiologically relevant contexts and stimuli are left with limited attention, resulting in a solution space constrained within the boundaries of presently manageable perturbations. To predict in the laboratory how a drug will work in a human patient, cell biology must have a closer look at life and strive to mimic the human being in all his complexity. By implementing an iterative process from perturbation to measurement and vice versa, the authors suggest using a sensor-extended imaging workflow to implement product development practices to cell biology, opening a physiologically relevant solution space for the development of truly translational and predictive fit for purpose in vitro cell models.
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. FDA. F. D. A. Modernization Act 2.0. (2022, September 29). (ed. 117th Congress (2021-2022)) (2022). The FDA claims in vivo experiments not any longer as mandatory for approval of new compounds (FDA, 2022).
2. Fuchs, S. et al. In-line analysis of organ-on-chip systems with sensors: integration, fabrication, challenges, and potential. ACS Biomater. Sci. Eng. 7, 2926–2948 (2021). Description of organ-on-chip system development with focus on cross-disciplinary work on in-line sensing.
3. Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics (Oxf., Engl.) 20, 273–286, https://doi.org/10.1093/biostatistics/kxx069 (2019).
4. Arango, M., Quintero-Ronderos, P., Castiblanco, J. & Montoya-Ortíz, G. in Autoimmunity: from Bench to Bedside. Ch. 19, 741–754 (El Rosario University Press, 2013).
5. Schueler, J. et al. How to build a tumor: an industry perspective. Drug Discov. today 27, 103329 (2022).